Taken together these data corroborate our hypothesis that Rab7a KO and TPC2 KO exert similar effects on cancer hallmarks and that the effect of Rab7a is mediated through TPC2, as the loss of Rab7a can be largely compensated with TPC2 agonist or overexpression but not vice versa. Here, TPCN2 is linked to cancer.